Portrazza

Portrazza Uses, Dosage, Side Effects, Food Interaction and all others data.

Portrazza is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Portrazza is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

Trade Name Portrazza
Availability Prescription only
Generic Necitumumab
Necitumumab Other Names Necitumumab
Related Drugs Opdivo, methotrexate, Keytruda, pembrolizumab, cisplatin, Tagrisso, Avastin
Weight 16mg/ml,
Type Intravenous solution
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Portrazza
Portrazza

Uses

Portrazza is a monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.

Portrazza is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.

Portrazza is also used to associated treatment for these conditions: Metastatic Non-Small Cell Lung Cancer

How Portrazza works

Portrazza is an EGFR antagonist that functions by binding to epidermal growth factor receptor (EGFR) and preventing binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation.

Toxicity

The poor safety profile of necitumumab has been one of the major limitations of its use. Rigorous monitoring of the following adverse events is recommended for the use of this drug: cardiopulmonary arrest, hypomagnesia, venous and arterial thromboembolic events, dermatologic toxicities, and infusion-related reactions. Due to observations of increased toxicity and mortality in treatment of non-squamous NSCLC, necitumumab is only recommended for the treatment of squamous NSCLC in combination with cisplatin and gemcitabine. Animal studies suggest potential embryo-fetal toxicity.

Food Interaction

No interactions found.

Volume of Distribution

Steady state volume of distribution is 7.0 L.

Half Life

Elimination half life is approximately 14 days.

Clearance

14.1 mL/h

Innovators Monograph

You find simplified version here Portrazza

*** Taking medicines without doctor's advice can cause long-term problems.
Share